The study, presented at the American Association for Cancer Research Molecular Diagnostics in Cancer Therapeutic Development meeting held here September 22-25, highlights the strong link between the virus and this cancer, which is common in Southern China and also develops in Chinese immigrants It further suggests that genetic levels of EBV should be assessed before and during treatment, not just after therapy, as it is now.
"We found that patients with undetectable EBV DNA mid-course through treatment had a greatly reduced risk of developing cancer recurrence two years after treatment, compared with patients with detectable EBV DNA," said the study's senior investigator, Anthony Chan, M.D., director of the Cancer Center at the Chinese University of Hong Kong.
Although EBV is associated with nasopharynx cancer, which develops in the upper area of the throat, a causal relationship hasn't been established, Chan says. Still, cancer cells contain EBV genetic material, which leaks into the bloodstream and can be detected using DNA tests. "That means a larger number of nasopharynx cancer cells in the body would give rise to a larger amount of EBV genetic material in the blood circulation, and so the EBV DNA level is a marker of the extent of cancer."
Researchers know that the amount of EBV DNA found after treatment is a recognized prognostic marker of survival because residual detectable EBV DNA "implies incomplete killing of cancer and thus a poor prognosis," Chan said. The question the researchers investigated is whether there is a way to identify patients with such a viral load before treatment is finished so that more aggressive therapy might be instituted.
"We need to know what to do for those patients with residual EBV. These patients usually do not have clinical evidence of cancer at that point and the residual cancer burden is at a microscopic level. Any extra treatment would be for undetectable cancer, and we need to prove that such treatment has an impact on improving survival," Chan said.
In this study, researchers tested 108 patients with advanced stage cancer for EBV DNA before the start of treatment, after a month of therapy, and then within three months after completion of treatment, and matched these levels to outcomes two-years later. They found that 94 percent of patients had detectable EBV DNA before therapy, but that it became undetectable in 54 percent of patients midway through treatment. The 42 percent of patients who had both low pretreatment and undetectable four-week viral levels constituted a "good risk group" because their recurrence rate was only nine percent.
Conversely, they found that levels detected after four weeks of treatment correlated with detectable post-treatment amounts, with an almost threefold greater risk of cancer recurrence and threefold higher risk of distant metastasis at two years.
"It is possible to test for EBV DNA levels at any time point, so based on further validation studies, we may be able to use biomarker levels at several time points to guide clinical therapy," Chan said.
Jeremy Moore | EurekAlert!
Newly designed molecule binds nitrogen
23.02.2018 | Julius-Maximilians-Universität Würzburg
Atomic Design by Water
23.02.2018 | Max-Planck-Institut für Eisenforschung GmbH
A newly developed laser technology has enabled physicists in the Laboratory for Attosecond Physics (jointly run by LMU Munich and the Max Planck Institute of Quantum Optics) to generate attosecond bursts of high-energy photons of unprecedented intensity. This has made it possible to observe the interaction of multiple photons in a single such pulse with electrons in the inner orbital shell of an atom.
In order to observe the ultrafast electron motion in the inner shells of atoms with short light pulses, the pulses must not only be ultrashort, but very...
A group of researchers led by Andrea Cavalleri at the Max Planck Institute for Structure and Dynamics of Matter (MPSD) in Hamburg has demonstrated a new method enabling precise measurements of the interatomic forces that hold crystalline solids together. The paper Probing the Interatomic Potential of Solids by Strong-Field Nonlinear Phononics, published online in Nature, explains how a terahertz-frequency laser pulse can drive very large deformations of the crystal.
By measuring the highly unusual atomic trajectories under extreme electromagnetic transients, the MPSD group could reconstruct how rigid the atomic bonds are...
Quantum computers may one day solve algorithmic problems which even the biggest supercomputers today can’t manage. But how do you test a quantum computer to...
For the first time, a team of researchers at the Max-Planck Institute (MPI) for Polymer Research in Mainz, Germany, has succeeded in making an integrated circuit (IC) from just a monolayer of a semiconducting polymer via a bottom-up, self-assembly approach.
In the self-assembly process, the semiconducting polymer arranges itself into an ordered monolayer in a transistor. The transistors are binary switches used...
Breakthrough provides a new concept of the design of molecular motors, sensors and electricity generators at nanoscale
Researchers from the Institute of Organic Chemistry and Biochemistry of the CAS (IOCB Prague), Institute of Physics of the CAS (IP CAS) and Palacký University...
15.02.2018 | Event News
13.02.2018 | Event News
12.02.2018 | Event News
23.02.2018 | Physics and Astronomy
23.02.2018 | Health and Medicine
23.02.2018 | Physics and Astronomy